

Nic Gillings

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6065699/publications.pdf>

Version: 2024-02-01

55
papers

1,675
citations

270111

25
h-index

340414

39
g-index

58
all docs

58
docs citations

58
times ranked

1821
citing authors

#	ARTICLE	IF	CITATIONS
1	EANM guideline on quality risk management for radiopharmaceuticals. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 3353-3364.	3.3	11
2	First-in-Humans PET Imaging of Tissue Factor in Patients with Primary and Metastatic Cancers Using ¹⁸ F-labeled Active-Site Inhibited Factor VII (¹⁸ F-ASIS): Potential as Companion Diagnostic. Journal of Nuclear Medicine, 2022, 63, 1871-1879.	2.8	3
3	On the consensus nomenclature rules for radiopharmaceutical chemistry – Reconsideration of radiochemical conversion. Nuclear Medicine and Biology, 2021, 93, 19-21.	0.3	43
4	Guideline on current good radiopharmacy practice (cGRPP) for the small-scale preparation of radiopharmaceuticals. EJNMMI Radiopharmacy and Chemistry, 2021, 6, 8.	1.8	58
5	Fully Automated GMP-Compliant Synthesis of [18F]FE-PE2I. Pharmaceuticals, 2021, 14, 601.	1.7	4
6	Insights into Elution of Anion Exchange Cartridges: Opening the Path toward Aliphatic ¹⁸ F-Radiolabeling of Base-Sensitive Tracers. ACS Pharmacology and Translational Science, 2021, 4, 1556-1566.	2.5	20
7	Highlight selection of radiochemistry and radiopharmacy developments by editorial board. EJNMMI Radiopharmacy and Chemistry, 2021, 6, 31.	1.8	0
8	Quality control of radiopharmaceuticals: Basics and instrumentation. , 2021, , .		0
9	<i>In Vivo Veritas</i> : ¹⁸ F-Radiolabeled Glycomimetics Allow Insights into the Pharmacological Fate of Galectin-3 Inhibitors. Journal of Medicinal Chemistry, 2020, 63, 747-755.	2.9	18
10	EANM guideline on the validation of analytical methods for radiopharmaceuticals. EJNMMI Radiopharmacy and Chemistry, 2020, 5, 7.	1.8	57
11	Measuring endogenous changes in serotonergic neurotransmission with [11C]Cimbi-36 positron emission tomography in humans. Translational Psychiatry, 2019, 9, 134.	2.4	40
12	The importance of small polar radiometabolites in molecular neuroimaging: A PET study with [¹¹ C]Cimbi-36 labeled in two positions. Journal of Cerebral Blood Flow and Metabolism, 2018, 38, 659-668.	2.4	23
13	¹⁸ F-Labeling of electron rich iodonium ylides: application to the radiosynthesis of potential 5-HT _{2A} receptor PET ligands. Organic and Biomolecular Chemistry, 2017, 15, 4351-4358.	1.5	15
14	Serotonin 2A receptor agonist binding with [11C]Cimbi-36 in the human brain is unaltered by citalopram/pindolol and acute tryptophan depletion. European Neuropsychopharmacology, 2016, 26, S307-S308.	0.3	2
15	Synthesis and evaluation of 18F-labeled 5-HT _{2A} receptor agonists as PET ligands. Nuclear Medicine and Biology, 2016, 43, 455-462.	0.3	18
16	^{99m} Tc-aprotinin - optimisation and validation of radiolabelling kits for routine preparation for diagnostic imaging of amyloidosis. Journal of Labelled Compounds and Radiopharmaceuticals, 2016, 59, 171-174.	0.5	1
17	Convergent 18F-labeling and evaluation of N-benzyl-phenethylamines as 5-HT _{2A} receptor PET ligands. Bioorganic and Medicinal Chemistry, 2016, 24, 5353-5356.	1.4	13
18	Serotonin 2A receptor agonist binding in the human brain with [11C]Cimbi-36: Test-retest reproducibility and head-to-head comparison with the antagonist [18F]altanserin. NeuroImage, 2016, 130, 167-174.	2.1	61

#	ARTICLE	IF	CITATIONS
19	Metabolic Fate of Hallucinogenic NBOMes. <i>Chemical Research in Toxicology</i> , 2016, 29, 96-100.	1.7	42
20	The Center for Integrated Molecular Brain Imaging (Cimbi) database. <i>NeuroImage</i> , 2016, 124, 1213-1219.	2.1	95
21	Efficient Regioselective Ring Opening of Activated Aziridine Carboxylates with [¹⁸ F]Fluoride. <i>ChemistryOpen</i> , 2015, 4, 65-71.	0.9	8
22	[⁶⁴ Cu]labelled trastuzumab: optimisation of labelling by DOTA and NODAGA conjugation and initial evaluation in mice. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2015, 58, 227-233.	0.5	16
23	BDNF Val66met and 5-HTTLPR polymorphisms predict a human in vivo marker for brain serotonin levels. <i>Human Brain Mapping</i> , 2015, 36, 313-323.	1.9	24
24	Simultaneous hyperpolarized (¹³ C)-pyruvate MRI and (¹⁸ F)-FDG-PET in cancer (hyperPET): feasibility of a new imaging concept using a clinical PET/MRI scanner. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 5, 38-45.	1.0	25
25	Accelerating preclinical PET-screening: reductive amination with [¹¹ C]methoxybenzaldehydes. <i>RSC Advances</i> , 2014, 4, 21347-21350.	1.7	10
26	Serotonin 2A Receptor Agonist Binding in the Human Brain with [¹¹ C]Cimbi-36. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2014, 34, 1188-1196.	2.4	88
27	Direct comparison of [¹⁸ F]MH.MZ and [¹⁸ F]altanserin for 5-HT _{2A} receptor imaging with PET. <i>Synapse</i> , 2013, 67, 328-337.	0.6	20
28	Radiotracers for positron emission tomography imaging. <i>Magnetic Resonance Materials in Physics, Biology, and Medicine</i> , 2013, 26, 149-158.	1.1	14
29	Optimisation of [¹¹ C]methane yields from a high pressure gas target. <i>AIP Conference Proceedings</i> , 2012, , .	0.3	5
30	Obesity is associated with high serotonin 4 receptor availability in the brain reward circuitry. <i>NeuroImage</i> , 2012, 61, 884-888.	2.1	59
31	5-HTTLPR status predictive of neocortical 5-HT ₄ binding assessed with [¹¹ C]SB207145 PET in humans. <i>NeuroImage</i> , 2012, 62, 130-136.	2.1	53
32	No change in [¹¹ C]CUMI-101 binding to 5-HT _{1A} receptors after intravenous citalopram in human. <i>Synapse</i> , 2012, 66, 880-884.	0.6	33
33	Direct radiofluorination of [¹⁸ F]MH.MZ for 5-HT _{2A} receptor molecular imaging with PET. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2012, 55, 354-358.	0.5	6
34	Evaluation of 4-[¹⁸ F]fluorobenzoyl-FALGEA-NH ₂ as a positron emission tomography tracer for epidermal growth factor receptor mutation variant III imaging in cancer. <i>Nuclear Medicine and Biology</i> , 2011, 38, 509-515.	0.3	15
35	Mass dose effects and in vivo affinity in brain PET receptor studies – a study of cerebral 5-HT ₄ receptor binding with [¹¹ C]SB207145. <i>Nuclear Medicine and Biology</i> , 2011, 38, 1085-1091.	0.3	48
36	Radiosynthesis and in vivo evaluation of a series of substituted ¹¹ C-phenethylamines as 5-HT _{2A} agonist PET tracers. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 681-693.	3.3	115

#	ARTICLE	IF	CITATIONS
37	Radiosynthesis and Evaluation of ¹¹ C-CIMBI-5 as a 5-HT _{2A} Receptor Agonist Radioligand for PET. <i>Journal of Nuclear Medicine</i> , 2010, 51, 1763-1770.	2.8	48
38	Fluorine- ¹⁸ labelling of a series of potential EGFR ^{IVL} targeting peptides with a parallel labelling approach using [¹⁸ F]FPyME. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2010, 53, 774-778.	0.5	7
39	Brain imaging of serotonin 4 receptors in humans with [¹¹ C]SB207145-PET. <i>NeuroImage</i> , 2010, 50, 855-861.	2.1	79
40	Tracer-dose limits and in vivo 5-HT ₄ receptor affinity in human brain PET studies with [¹¹ C]SB207145. <i>NeuroImage</i> , 2010, 52, S193.	2.1	1
41	Radiosynthesis and ex vivo evaluation of (R)-(¹¹ C)-2-chloro-N-[1- ¹¹ C-propyl]n-propylnorapomorphine. <i>Nuclear Medicine and Biology</i> , 2010, 37, 35-40.	0.3	2
42	A quartz-lined carbon-11 target: striving for increased yield and specific activity. <i>Nuclear Medicine and Biology</i> , 2010, 37, 943-948.	0.3	13
43	Kinetic Modeling of ¹¹ C-SB207145 Binding to 5-HT ₄ Receptors in the Human Brain In Vivo. <i>Journal of Nuclear Medicine</i> , 2009, 50, 900-908.	2.8	84
44	HPLC methods for the purification of [¹¹ C]-labelled radiopharmaceuticals: reversal of the retention order of products and precursors. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2009, 52, 177-181.	0.5	12
45	Identification of novel peptide ligands for the cancer-specific receptor mutation EGFR ^{IVL} using a mixture-based synthetic combinatorial library. <i>Biopolymers</i> , 2009, 91, 201-206.	1.2	24
46	Evaluation of the Novel 5-HT ₄ Receptor PET Ligand [¹¹ C]SB207145 in the Göttingen Minipig. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2009, 29, 186-196.	2.4	52
47	A restricted access material for rapid analysis of [¹¹ C]-labeled radiopharmaceuticals and their metabolites in plasma. <i>Nuclear Medicine and Biology</i> , 2009, 36, 961-965.	0.3	42
48	Identification of Amino Acid Residues in PEPHC1 Important for Binding to the Tumor-specific Receptor EGFR ^{IVL} . <i>Chemical Biology and Drug Design</i> , 2008, 72, 273-278.	1.5	3
49	Synthesis of (R)-(-)-2-Fluoronorapomorphine – A Precursor for the Synthesis of (R)-(-)-2-Fluoro-N-[¹¹ C]propylnorapomorphine for Evaluation as a Dopamine D ₂ Agonist Ligand for PET Investigations. <i>European Journal of Organic Chemistry</i> , 2005, 2005, 4428-4433.	1.2	16
50	Binding characteristics of the 5-HT _{2A} receptor antagonists altanserin and MDL 100907. <i>Synapse</i> , 2005, 58, 249-257.	0.6	55
51	Synthesis and binding studies of 2-arylpropomorphines. <i>Organic and Biomolecular Chemistry</i> , 2005, 3, 4077.	1.5	29
52	Kinetics of the uptake and distribution of the dopamine D _{2,3} agonist (R)-N-[¹¹ C]n-propylnorapomorphine in brain of healthy and MPTP-treated Göttingen miniature pigs. <i>Nuclear Medicine and Biology</i> , 2003, 30, 547-553.	0.3	31
53	The Competition Between Endogenous Dopamine and Radioligands for Specific Binding to Dopamine Receptors. <i>Annals of the New York Academy of Sciences</i> , 2002, 965, 440-450.	1.8	28
54	Kinetics of the metabolism of four PET radioligands in living minipigs. <i>Nuclear Medicine and Biology</i> , 2001, 28, 97-104.	0.3	43

#	ARTICLE	IF	CITATIONS
55	Normalization of markers for dopamine innervation in striatum of MPTP-lesioned miniature pigs with intrastriatal grafts. <i>Acta Neurologica Scandinavica</i> , 2001, 103, 309-315.	1.0	38